Mp44-11 Prognostic Impact of Lung Immune Prognostic Index in Recurrence After Radical Surgery for High-Risk Renal Cell Carcinoma

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy III (MP44)1 May 2024MP44-11 PROGNOSTIC IMPACT OF LUNG IMMUNE PROGNOSTIC INDEX IN RECURRENCE AFTER RADICAL SURGERY FOR HIGH-RISK RENAL CELL CARCINOMA Yudai Ishiyama, Hiroki Ishihara, Tsunenori Kondo, Kazuhiko Yoshida, Junpei Iizuka, and Toshio Takagi Yudai IshiyamaYudai Ishiyama , Hiroki IshiharaHiroki Ishihara , Tsunenori KondoTsunenori Kondo , Kazuhiko YoshidaKazuhiko Yoshida , Junpei IizukaJunpei Iizuka , and Toshio TakagiToshio Takagi View All Author Informationhttps://doi.org/10.1097/01.JU.0001009508.69111.d0.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: As new options are becoming available in immediate post-operative setting for high-risk renal cell carcinoma (hrRCC), identification of the highest-risk cohort may be clinically relevant as adjuvant immunotherapy is suggested to be even more beneficial among this population. We evaluated the impact of lung immune prognostic index (LIPI), a novel prognostic score, in this setting. METHODS: This multi-institutional retrospective study recruited 235 patients who underwent radical surgery for hrRCC (pT3 or higher, N0-2, M0) between 2004 and 2021. LIPI scores were calculated based on the dNLR (neutrophil/WBC-neutrophil) and the LDH level. The association between LIPI and local or distant recurrence were analyzed, along with other possible clinical factors using the Cox hazards model. RESULTS: The median recurrence-free survival (RFS) was 36.4 [95% CI: 29.6–63.8] months. Based on the LIPI, 119 (50.6%), 91 (38.7%) and 25 (10.6%) patients were each allocated to good (score=0), intermediate (=1), and poor (=2) groups, respectively. The RFS were significantly correlated with the LIPI scores (median PFS: 90.8 vs. 21.2 vs. 10.0 months, p<0.001), and at 50.0 months all the patients in the poor groups were either recurred or censored, compared to 42.5% in the good or 67.0% in intermediate. LIPI was shown to be a independent predictor of RFS when analyzed in the multivariable Cox hazard model. Significant improvement of C-index was shown when adding LIPI to the existing UISS score (0.629 to 0.701). CONCLUSIONS: LIPI could be a significant prognostic biomarker for recurrence prediction in hrRCC, particularly in identifying the highest-risk cohort. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e734 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Yudai Ishiyama More articles by this author Hiroki Ishihara More articles by this author Tsunenori Kondo More articles by this author Kazuhiko Yoshida More articles by this author Junpei Iizuka More articles by this author Toshio Takagi More articles by this author Expand All Advertisement PDF downloadLoading ...